Efficacy and Safety of Bictegravir-Based Regimen in Pregnant Women Living with HIV: A Case Report.
J Int Assoc Provid AIDS Care
; 21: 23259582221146110, 2022.
Article
em En
| MEDLINE
| ID: mdl-36529886
ABSTRACT
Bictegravir (BIC) is included in international guidelines as the first line of therapy for patients living with Human Immunodeficiency Virus (HIV), either as initial therapy or as a replacement for patients with prior antiretroviral therapy (ART). Due to limited efficacy and safety data, BIC is currently not recommended during pregnancy. Data on the safety and efficacy of BIC during pregnancy were unavailable at the time of drug approval. In our case, BIC/TAF/FTC was effective in suppressing viral load (VL) in pregnancy, and there were no reported safety issues for the mother or the baby.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
HIV-1
/
Fármacos Anti-HIV
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article